Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2011

View Archived Issues

Sanofi discloses novel agents for diabetic foot ulcers

Novel Novartis product enters phase I/II trial in healthy subjects and patients with diabetes

Roche discovers new phosphodiesterase 10A inhibitors

New histone deacetylase 9 inhibitors claimed

Novel B-raf inhibitors patented by Selexagen

NCCU patents new beta-nerve growth factor enhancers

FDA clears Newron to conduct first-in-human study of add-on therapy for schizophrenia

U.S. Department of Defense funds development of NeoStem stem cell technology for osteoporosis

New urine-based biomarker test predicts risk of prostate cancer in men with elevated PSA

GSK submits sNDA in U.S. for use of Horizant

Pluristem's agreement with United Therapeutics for PLX cells is effective

Amarin reaches SPA agreement with FDA for phase III REDUCE-IT trial

Array BioPharma and Genentech enter agreement for Chk1 program

NCI to sponsor clinical trials of Pharmacyclics BTK inhibitor

Ironwood Pharmaceuticals and Forest Laboratories submit linaclotide NDA for two indications

Novel injectable coacervate induces angiogenesis in vivo

Enobia raises funds for development of ENB-0040

Chugai files application for additional indication for Kytril in Japan

ThromboGenics expects ocriplasmin filings in U.S. and E.U. before year-end

Adventrx receives FDA complete response letter for Exelbine

New phase I trial of anticancer drug TKM-PLK1 cleared by FDA

Glenmark Pharmaceuticals initiates global phase IIb trials of revamilast

GWAS identifies new lung cancer susceptibility loci in Chinese population

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...